Provided by Tiger Trade Technology Pte. Ltd.

LivaNova PLC

80.63
+2.453.13%
Post-market: 80.19-0.4400-0.55%19:52 EDT
Volume:553.52K
Turnover:44.28M
Market Cap:4.43B
PE:23.78
High:80.77
Open:78.70
Low:78.30
Close:78.18
52wk High:85.76
52wk Low:48.82
Shares:54.93M
Float Shares:54.68M
Volume Ratio:1.13
T/O Rate:1.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.39
EPS(LYR):-4.4500
ROE:15.40%
ROA:5.04%
PB:3.34
PE(LYR):-18.12

Loading ...

LivaNova Shares Rise After Outlook Boost

Dow Jones
·
May 06

Stock Track | LivaNova Soars 6.79% in Pre-market on Strong Q1 Earnings Beat and Raised Guidance

Stock Track
·
May 06

UK's LivaNova Q1 revenue beats analyst estimates

Reuters
·
May 06

LivaNova Q1 Adj. EPS $0.98 Beats $0.90 Estimate, Sales $362.300M Beat $346.108M Estimate

Benzinga Earnings
·
May 06

BRIEF-LivaNova Q1 Adjusted EPS USD 0.98 Vs. IBES Estimate USD 0.9

Reuters
·
May 06

LivaNova Q1 Adjusted EPS USD 0.98 VS. Ibes Estimate USD 0.9

THOMSON REUTERS
·
May 06

LivaNova Q1 EPS USD 0.4

THOMSON REUTERS
·
May 06

Press Release: LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Dow Jones
·
May 06

Earning Preview: LivaNova PLC Q1 revenue is expected to increase by 14.48%, and institutional views are predominantly bullish

Earnings Agent
·
Apr 30

Annals publishes 12-month OSPREY trial data for LivaNova sleep apnea device

Reuters
·
Apr 21

Annals of Internal Medicine Publishes 12-Month Results From LivaNova’s Osprey Clinical Study for Obstructive Sleep Apnea

THOMSON REUTERS
·
Apr 21

Press Release: LivaNova to Announce First-Quarter 2026 Results

Dow Jones
·
Mar 25

LivaNova schedules a conference call on first-quarter FY2026 results; access code set at 946097

Reuters
·
Mar 25

A Look At LivaNova (LIVN) Valuation After Recent Share Price Weakness

Simply Wall St.
·
Mar 25

LivaNova wins FDA PMA approval for aura6000 obstructive sleep apnea system

Reuters
·
Mar 19

LivaNova Plc - Next-Gen Mri-Compatible Device Expected to Launch in First Half of 2027 Pending FDA Review

THOMSON REUTERS
·
Mar 19

LivaNova Receives U.S. Food and Drug Administration Premarket Approval for Aura6000 System to Treat Moderate to Severe Obstructive Sleep Apnea

THOMSON REUTERS
·
Mar 19